<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PANCRELIPASE <img border="0" src="../images/pr.gif"/></span><br/>(pan-kre-li'pase)<br/><span class="topboxtradename">Cotazym, </span><span class="topboxtradename">Cotazym-S, </span><span class="topboxtradename">Festal II, </span><span class="topboxtradename">Ilozyme, </span><span class="topboxtradename">Ku-Zyme-Hp, </span><span class="topboxtradename">Pancrease, </span><span class="topboxtradename">Ultrase, </span><span class="topboxtradename">Viokase<br/></span><b>Classifications:</b> <span class="classification">enzymes</span>; <span class="classification">enzyme replacement therapy</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>Tablets or capsules containing lipase, protease, and amylase</p>
<h1><a name="action">Actions</a></h1>
<p>Pancreatic enzyme concentrate of porcine origin standardized for lipase content. Similar to pancreatin but on a weight basis
         has 12 times the lipolytic activity and at least 4 times the trypsin and amylase content of pancreatin.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Facilitates the hydrolysis of fats into glycerol and fatty acids, starches into dextrins and sugars, and proteins into peptides
         for easier absorption.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Replacement therapy in symptomatic treatment of malabsorption syndrome due to cystic fibrosis and other conditions associated
         with exocrine pancreatic insufficiency.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of allergy to hog protein or enzymes; esophageal strictures; pancreatitis; porcine protein hypersensitivity; pregnancy
         (category C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Pancreatic Insufficiency</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 13 capsules or tablets or 12 packets of powder 12 h before, during, or 1 h after meals, with an extra dose
               taken with any food eaten between meals<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 12 capsules or tablets 12 h before, during, or 1 h after meals, with an extra dose taken with any food eaten between
               meals<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Ensure that enteric-coated preparations are not crushed or chewed.</li>
<li> 				Note: For children, powder form may be sprinkled on food. 			</li>
<li>Open capsule and sprinkled contents on soft food, which should be swallowed without chewing to prevent mucus membrane irritation.
            Follow with a full glass of water or juice. Cimetidine, ranitidine, or an antacid may be prescribed to be given before pancrelipase
            to prevent drug's destruction by gastric pepsin and acid pH.
         </li>
<li>Determine dosage in relation to fat content in diet (suggested ratio: 300 mg pancrelipase for each 17 g dietary fat).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span> Anorexia, nausea, vomiting, diarrhea. <span class="typehead">Metabolic:</span> Hyperuricosuria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Iron</b> absorption may be decreased. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Not absorbed. <span class="typehead">Distribution:</span> acts locally in GI tract. <span class="typehead">Elimination:</span> Excreted in feces. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor I&amp;O and weight. Note appetite and quality of stools, weight loss, abdominal bloating, polyuria, thirst, hunger, itching.
            Pancreatic insufficiency is frequently associated with steatorrhea, bulky stools, and insulin-dependent diabetes.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn proper timing of medication in relation to meals.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>